3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
21
Rectal Neoplasms
10
Colonic Neoplasms
6
Pancreatic Neoplasms
4
Stomach Neoplasms
3
Neoplasm Metastasis
3
Adenocarcinoma Of Esophagus
3
Peritoneal Neoplasms
2
Neoplasms
2
Liver Neoplasms
2
Esophageal Neoplasms
2
Pancreatic Adenocarcinoma
1
Ovarian Neoplasms
1
Neuropathy, Painful
1
Neuralgia
1
Neoplasm Recurrence, Local
1
Malignant Solid Tumour
1
Locally Advanced Pancreatic Carcinoma(LAPC)
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Disease Progression
1
Cold Hypersensitivity
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Advanced Rectal Cancer
1
Advanced Primary Liver Cancer
1
Adenocarcinoma of the Lower Rectum
1
Interventions
Gemcitabine
19
Cisplatin
11
Capecitabine
9
Oxaliplatin
7
Fluorouracil
5
pembrolizumab
4
Leucovorin
4
Sorafenib
3
Magnetic Resonance Spectroscopy
3
Erlotinib Hydrochloride
3
trifluridine tipiracil drug combination
2
regorafenib
2
cobimetinib
2
atezolizumab
2
Trastuzumab
2
Taxes
2
Specimen Handling
2
Platinum
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Lapatinib
2
Biopsy
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
1,2-diaminocyclohexaneplatinum II citrate
2
zanidatamab
1
varlilumab
1
vandetanib
1
tucatinib
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Gallbladder Neoplasms
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts